Results 11 to 20 of about 6,214,933 (159)

Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy [PDF]

open access: yesTherapeutics and Clinical Risk Management, 2020
Nicola Specchio, Nicola Pietrafusa, Marina Trivisano Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome, ItalyCorrespondence: Nicola SpecchioDepartment of Neuroscience, Bambino Ges ...
Specchio N, Pietrafusa N, Trivisano M
doaj   +6 more sources

A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies. [PDF]

open access: yesPLoS ONE, 2017
The Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, result from mutations in over a dozen genes. Although, adults are susceptible, the NCLs are frequently classified as pediatric neurodegenerative diseases due to their greater ...
Ryan D Geraets   +7 more
doaj   +7 more sources

Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa [PDF]

open access: yesFrontiers in Neurology
IntroductionThis study assessed the real-world effectiveness and safety of the enzyme replacement therapy (ERT), cerliponase alfa, to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease.MethodsData from the DEM-CHILD database were analyzed ...
Angela Schulz   +11 more
doaj   +6 more sources

Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis? [PDF]

open access: yesNeuropediatrics, 2023
AbstractNeuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric disorder associated with rapid neurodegeneration, and premature death in adolescence. An effective enzyme replacement therapy (cerliponase alfa) has been approved that can reduce this predictable neurological decline.
Nickel, Miriam   +9 more
europepmc   +7 more sources

Neurofilament light is a treatment‐responsive biomarker in CLN2 disease [PDF]

open access: yesAnnals of Clinical and Translational Neurology, 2019
Objective Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, progressive, fatal neurodegenerative pediatric disorder resulting from deficiencies of the lysosomal enzyme tripeptidyl peptidase 1 that are caused by mutations in TPP1 ...
Yuanbin Ru   +12 more
doaj   +4 more sources

Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2021
Background CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1).
Sara E. Mole   +20 more
doaj   +7 more sources

Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series [PDF]

open access: yesJournal of Child Neurology, 2020
Background: The classic phenotype of CLN2 disease (neuronal ceroid lipofuscinosis type 2) typically manifests between ages 2 and 4 years with a predictable clinical course marked by epilepsy, language developmental delay, and rapid psychomotor decline.
Eva Wibbeler   +15 more
europepmc   +9 more sources

Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom [PDF]

open access: yesOrphanet Journal of Rare Diseases
Background Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, are a group of inherited neurodegenerative disorders that mostly arise in childhood.
Sara E. Mole   +14 more
doaj   +18 more sources

GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice [PDF]

open access: yesJCI Insight
The cellular etiology of seizures in CLN2 disease, a childhood-onset neurodegenerative lysosomal storage disorder caused by a deficiency of tripeptidyl peptidase 1 (TPP1), remains elusive.
Keigo Takahashi   +13 more
doaj   +6 more sources

Visual perception and macular integrity in non-classical CLN2 disease [PDF]

open access: yesGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
Abstract Purpose Patients with CLN2 suffer from epileptic seizures, rapid psychomotor decline and vision loss in early childhood. The aim of the study was to provide longitudinal ophthalmic data of patients with confirmed genetic mutation and non-classical disease course, marked by later onset, protracted progression and
Yevgeniya Atiskova   +7 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy